A massive $85 billion acquisition was finalized in December 2025, where a leading pharmaceutical giant (like Pfizer or Eli Lilly) acquired a top-tier CRISPR technology firm. This marked the beginning of a “personalized medicine” era, with exclusive patent rights to several new gene-editing therapies for rare diseases.
The Mega-Merger in Biotech
